Gil Y. Roth || September 3, 2009 I've done a bang-up job of staying out of this summer's rancorous "debates" over healthcare reform, and plan to stay on that path. So don't try to get me wound up.
The thing is, I don't doubt the sincerity of citizens on both sides of the is…
July 15, 2009 This edition of the Top 10 Biopharmas marks the end of an era. After this year, we’ll no longer be able to pencil in Amgen as our #1 biopharma, since Roche is poised to take that slot. A lot of major pharmas have talked about “becoming a global biopharma.
July 15, 2009 They don’t call them “Big Pharma” for nothing! Several of the industry’s biggest players decided to get bigger via M&A this year, which means next year’s ranks are going to feature at least three new players, once Wyeth and Schering-Plough are swallowed up and Roche moves over to the Top Biopharma ranks. And I do mean top!
Gil Roth, Editor || May 15, 2009 Welcome to our 5th Annual Contract Pharma Outsourcing Survey! More than 175 sponsor-side respondents offered up their opinions on outsourcing trends for this year's poll. Here's a breakdown of respondents by company type:
April 27, 2009 Novozymes Biopharma has begun construction of a new cGMP facility at its existing site in Tianjin, China, enabling the company to produce Bacillus-based Hyaluronic Acid (bHA), HyaCare, for the bio-medical and pharmaceutical industries.
January 22, 2009 Rick Lapointe has been appointed vice president of technology and acquisitions at OSO BioPharmaceuticals Manufacturing. Mr. Lapointe will be responsible for working with the senior leadership team to increase the company’s capabilities, identif…
Eric S. Langer || November 6, 2008 Bio News & Views: Bio-Outsourcing Trends
A new study explores capacity and production issues
By Eric S. Langer
Outsourcing biopharmaceutical production has become increasingly common during the past decade, with more than half of…
August 20, 2008 Bristol-Myers Squibb and PDL BioPharma, Inc. entered an agreement for the global development and commercialization of PDL’s anti-CS1 antibody, elotuzumab, currently in Phase I development for multiple myeloma.
July 18, 2008 The weak U.S. dollar played a strong role in this year’s Top 20 Pharma Report. Several overseas players look a lot better than they should, thanks to my insistence on converting all results to dollars. In local currencies, many foreign and domestic players were barely able to eke out growth in 2007.
July 18, 2008 After years of producing this report, I’ve finally settled on definitive criteria for the Top Biopharma ranks! After consulting with Ronald A. Rader, president of the Biotechnology Information Institute, I decided that a Top Biopharma company is one that makes more than 40% of its drug revenues by selling biologic products, including biotherapeutics, vaccines and other proteins.